Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease - (JAMA)
    TopAbstracts in Depression 11/26/2008 - (DGNews)
    Change in Health Behaviours May Link Depression and Cardiovascular Events - (DGNews)
    Fluoxetine, Paroxetine Associated With Increased Risk of Foetal Heart Anomalies - (DGNews)
    TopAbstracts in Depression 11/19/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Depression

    Webcasts/CME archive

     Recent cases - Depression
      Sexual Dysfunction in a Young Mother
      Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
      A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
      Affective Psychosis, Hashimoto's Thyroiditis, and Brain Perfusion Abnormalities: Case Report
      Dissecting the Determinants of Depressive Disorders Outcome: An in Depth Analysis of Two Clinical Cases

      Cases archive
        




      my personal edition > depression > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Fluoxetine Treatment For Depression Should Continue For Set Period For Proper Assessment

      A DGReview of :"When should a trial of fluoxetine for major depression be declared failed?"
      American Journal of Psychiatry

      04/09/2003
      By David Ball


      Patients with major depression who are being treated with fluoxetine should continue therapy for eight weeks before non-response is pronounced, say researchers in the United States.

      Little is known about how long it takes for the widely used newer antidepressants to show their full effect so trial length should be discussed by clinicians and their patients at the start of therapy. This is suggested by F. M. Quitkin and colleagues at the Columbia University, New York State Psychiatric Institute.

      In their 12-week open trial of fluoxetine involving data on 840 patients, the researchers tested the number of weeks treatment should continue with no improvement before it was changed. A blinded, placebo-controlled discontinuation study followed the trial treatment of 20 mg a day fluoxetine.

      Based on Hamilton Depression Rating Scale scores, outcomes were classified as non-response, partial response, response and remission at 4, 6, 8, 10 and 12 weeks. At week 12 the rate of remission was calculated for each group of subjects with no remission at the previous time points.

      In the discontinuation study, the time to relapse during weeks 13 to 26 was checked in those taking placebo and fluoxetine in relation to status at week 6. A remission rate of 31 to 41% was found in subjects who were unimproved at week 6.

      The level of improvement at week 6 was seen not to affect prognosis in weeks 13 to 26 in patients with remission at week 12. For those who were unimproved at week 8, 23% were found to have remissions by week 12.

      Continued treatment was clearly justified for those subjects who were unimproved at week 4 by the high remission rate in week 12.

      For unimproved patients at week 10, however, the rate was too low.
      Am J Psychiatry 2003 Apr;160:4:734-40. "When should a trial of fluoxetine for major depression be declared failed?"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send